Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2011.06.013DOI Listing

Publication Analysis

Top Keywords

narcoleptic-like hypersomnia
4
hypersomnia inverted
4
inverted circadian
4
circadian rhythm
4
rhythm body
4
body core
4
core temperature
4
temperature traumatic
4
traumatic brain
4
brain injury
4

Similar Publications

Introduction: Excessive daytime sleepiness (EDS) is a common and debilitating symptom in both forms of myotonic dystrophy (DM), significantly impacting patients' quality of life. The review focuses on the purpose of examining the current understanding of EDS in these conditions, the difficulty in correctly accessing it, the recent findings related to its etiology and prevalence, and a summary of potential therapeutic implications.

Methods: We conducted a comprehensive search through PubMed, selecting studies that provided significant insights into the mechanisms, prevalence, and management of EDS in DM1 and DM2.

View Article and Find Full Text PDF

Unlabelled: One of the main manifestations of excessive daytime sleepiness (EDS) among patients with Parkinson's disease is sudden-onset sleep (SOS). The SOS episodes could dramatically increase the traumatic ratio among those patients. The factors of SOS among PD patients are not well understood.

View Article and Find Full Text PDF

Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretindeficient Rats: Preliminary Data.

CNS Neurol Disord Drug Targets

September 2020

Depto. de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.

Background: Excessive daytime sleepiness and cataplexy are among the symptoms of narcolepsy, a sleep disorder caused by the loss of hypocretin/orexin (HCRT/OX) neurons placed into the Hypothalamus (LH). Several treatments for managing narcolepsy include diverse drugs to induce alertness, such as antidepressants, amphetamine, or modafinil, etc. Recent evidence has shown that cannabidiol (CBD), a non-psychotropic derived from Cannabis sativa, shows positive therapeutic effects in neurodegenerative disorders, including Parkinson´s disease.

View Article and Find Full Text PDF

Purpose Of Review: To update current knowledge regarding sleep disturbances and myotonic dystrophies so as to better understand if sleep symptoms may help in the early recognition of the two genetic subtypes: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).

Recent Findings: Sleep-disordered breathing (SDB), restless legs syndrome, periodic limb movements in sleep, hypersomnia, and REM sleep dysregulation are frequently described in DM1 patients. SDB does not always explain hypersomnia, but a central dysregulation of sleep-wake modulation is reported mainly in DM1.

View Article and Find Full Text PDF

Myotonic dystrophytype 1 - report of non-24-h sleep-wake disorder with excessive daytime sleepiness.

Chronobiol Int

September 2018

a Departamento de Neurologia e Neurocirurgia , Universidade Federal de São Paulo , São Paulo , Brasil.

Article Synopsis
  • Myotonic dystrophy (MD) is a condition that affects muscles and the central nervous system, leading to symptoms like muscle weakness and excessive daytime sleepiness (EDS).
  • In a case study of a 26-year-old female with MD type 1, it was found that EDS was linked to both sleep-related disorders and a central dysfunction in sleep regulation.
  • Treatment with the medication agomelatine improved her sleep patterns and reduced sleepiness, highlighting the importance of identifying circadian rhythm disorders for effective treatment in patients with MD and EDS.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!